Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 47Glioblastoma 47Breast Neoplasms 40Esophageal Neoplasms 36Rectal Neoplasms 35Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 33Head and Neck Neoplasms 29Squamous Cell Carcinoma of Head and Neck 26Brain Neoplasms 23Pancreatic Neoplasms 22Neoplasms 19Uterine Cervical Neoplasms 17Oropharyngeal Neoplasms 16Neoplasm Metastasis 16Gliosarcoma 16Esophageal Squamous Cell Carcinoma 16Glioma 15Sarcoma 14Melanoma 14Stomach Neoplasms 12Adenocarcinoma Of Esophagus 12Lymphoma, Follicular 9Carcinoma, Squamous Cell 9Mouth Neoplasms 8Lymphoma, B-Cell, Marginal Zone 8Anus Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myeloid, Acute 7Endometrial Neoplasms 7

Interventions

pembrolizumab 3lenvatinib 3gallium 68 PSMA-11 2apatinib 2Protons 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Epirubicin 2Cisplatin 2Carboplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 2tislelizumab 1regorafenib 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1abemaciclib 1Tretinoin 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sunitinib 1Standard of Care 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Radiation 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Adenoid Cystic × Radiation × Clear all
NCT03087019 2022-10-14

Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma

Dana-Farber Cancer Institute

Phase 2 Completed
21 enrolled 11 charts

Carcinoma, Adenoid Cystic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡